Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview 8 Therapeutics Development 9 Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Overview 9 Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis 10 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Development by Companies 11 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 12 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Development by Companies 15 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Investigation by Universities/Institutes 16 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Companies Involved in Therapeutics Development 17 CEL-SCI Corporation 17 GeneCure LLC 18 Humabs BioMed SA 19 Inovio Pharmaceuticals, Inc. 20 Nanotherapeutics, Inc. 21 Novavax, Inc. 22 Phelix Therapeutics, LLC 23 Protein Sciences Corporation 24 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 CEL-1000 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 D-3252 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 FDX-000 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 INO-4500 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 LCA-60 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 middle east respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ML-188 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Monoclonal Antibody for SARS Virus Infections - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 RBD-219N1 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 SARS (virus like particle) vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 SARS vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SARS vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 severe acute respiratory syndrome vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SSYA-10001 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 thiocarbazate - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Recent Pipeline Updates 53 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects 54 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products 56 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Product Development Milestones 57 Featured News & Press Releases 57 Oct 19, 2015: Inovio and Partner Advance MERS Vaccine 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59

List of Tables Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H1 2016 9 Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by CEL-SCI Corporation, H1 2016 17 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by GeneCure LLC, H1 2016 18 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2016 19 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 20 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Nanotherapeutics, Inc., H1 2016 21 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Novavax, Inc., H1 2016 22 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H1 2016 23 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Protein Sciences Corporation, H1 2016 24 Assessment by Monotherapy Products, H1 2016 25 Assessment by Combination Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2016 53 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects, H1 2016 54 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects (Contd..1), H1 2016 55 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products, H1 2016 56 List of Figures Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H1 2016 9 Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 25 Number of Products by Targets, H1 2016 27 Number of Products by Stage and Targets, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 29 Number of Products by Stage and Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Top 10 Molecule Types, H1 2016 33 Number of Products by Stage and Top 10 Molecule Types, H1 2016 33

CEL-SCI Corporation GeneCure LLC Humabs BioMed SA Inovio Pharmaceuticals, Inc. Nanotherapeutics, Inc. Novavax, Inc. Phelix Therapeutics, LLC Protein Sciences Corporation